Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Novartis | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Novartis

Pharmaceutical sales up 2% driven by Entresto, Cosentyx and Zolgensma.

By: Contract Pharma

Contract Pharma Staff

Novartis

3Q Revenues: $12.3 billion (+1%)

3Q Earnings: $1.9 billion (-5%)

YTD Revenues: $35.9 billion (+2 %)

YTD Earnings: $6.0 billion (-44%)

Comments: Growth drivers in the quarter included Entresto $632 million (+45% cc), Zolgensma $291 million (+79% cc), Cosentyx $1.0 billion (+7% cc), Kisqali $183 million (+50% cc) and Promacta/Revolade $442 million (+16% cc). Sandoz Biopharmaceuticals grew 13% with growth across all regions. Innovative Medicines sales were $9.8 billion (+2%) with volume contributing 9 percentage points to growth, pricing had a negative impact of 5 percentage points and generic competition had a negative impact of 3 percentage points mainly due to Afinitor and Exjade. Pharmaceutical sales grew 2% (cc) driven by Entresto, Cosentyx and Zolgensma. Growth was partly offset by declines in Established Medicines and ophthalmology brands. Oncology sales were in line with prior year (-1% cc). Strong performance of Kisqali, Promacta/Revolade, Jakavi, Tafinlar + Mekinist and Piqray was offset by generic competition for Afinitor and Exjade. The COVID-19 pandemic continued to negatively impact dermatology and ophthalmology. In the quarter, Kesimpta was approved and launched in the U.S. for treatment of relapsing forms of multiple sclerosis. Piqray received EC approval for HR+/HER2- advanced breast cancer with a PIK3CA mutation.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters